Warning: Undefined variable $sector_url in /var/www/html/macrotrends/public_html/production/stock_metadata.php on line 1234

Warning: Undefined variable $base_url in /var/www/html/macrotrends/public_html/production/stock_metadata.php on line 1245

Warning: Undefined variable $industry_url in /var/www/html/macrotrends/public_html/production/stock_metadata.php on line 1247

Warning: Undefined variable $base_url in /var/www/html/macrotrends/public_html/production/stock_metadata.php on line 1261

Warning: Undefined variable $page_highlight in /var/www/html/macrotrends/public_html/production/stock_metadata.php on line 1348

Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in /var/www/html/macrotrends/public_html/production/master_chart_page.php on line 308
Biofrontera P/S Ratio 2021-2025 | BFRI | MacroTrends

Biofrontera P/S Ratio 2021-2025 | BFRI

Biofrontera p/s ratio from 2021 to 2025. P/s ratio can be defined as the price to sales or PS ratio is calculated by taking the latest closing price and dividing it by the most recent sales per share number. The PS ratio is an additional way to assess whether a stock is over or under valued and is used primarily in cases where earnings are negative and the PE ratio cannot be utilized.

Biofrontera P/S Ratio 2021-2025 | BFRI

Biofrontera p/s ratio from 2021 to 2025. P/s ratio can be defined as the price to sales or PS ratio is calculated by taking the latest closing price and dividing it by the most recent sales per share number. The PS ratio is an additional way to assess whether a stock is over or under valued and is used primarily in cases where earnings are negative and the PE ratio cannot be utilized.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$209.6B
Amgen (AMGN)$149.1B
Gilead Sciences (GILD)$130.2B
Vertex Pharmaceuticals (VRTX)$125.6B
Bristol Myers Squibb (BMY)$100.2B
CSL (CSLLY)$74.3B
GSK (GSK)$74.1B
Regeneron Pharmaceuticals (REGN)$61.6B
Argenex SE (ARGX)$36.2B
Alnylam Pharmaceuticals (ALNY)$30.5B
BioNTech SE (BNTX)$23.7B
BeiGene (ONC)$22.8B
Biogen (BIIB)$17.4B
Genmab (GMAB)$13.3B
Genmab (GNMSF)$13.3B
Insmed (INSM)$13.2B
BioMarin Pharmaceutical (BMRN)$11.3B
Illumina (ILMN)$11.3B
Incyte (INCY)$11.3B
Ascendis Pharma (ASND)$10.1B
Exelixis (EXEL)$10B
Swedish Orphan Biovitrum (BIOVF)$9.6B
Moderna (MRNA)$9.6B
QIAGEN (QGEN)$9B
Exact Sciences (EXAS)$7.7B
Bio-Techne Corp (TECH)$7.6B
Repligen (RGEN)$7.3B
Halozyme Therapeutics (HALO)$7.3B
Roivant Sciences (ROIV)$7.2B
Revolution Medicines (RVMD)$6.8B